<DOC>
	<DOCNO>NCT00958269</DOCNO>
	<brief_summary>The purpose study assess safety tolerability dutogliptin Type 2 diabetic subject moderate severe renal impairment .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Dutogliptin Type 2 Diabetes Mellitus Subjects With Moderate Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Type 2 diabetes mellitus Renal impairment ( moderate severe ) Currently stable dos background medication SU , TZD , acarbose , meglitinide , insulin combination thereof , antidiabetic drug HbA1c 7.0 % 10.5 % , inclusive Male female subject age 18 85 year , inclusive . Type 1 diabetes mellitus history diabetic ketoacidosis , mature onset diabetes young ( MODY ) Kidney transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>diabetes</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>dutogliptin</keyword>
	<keyword>PHX1149</keyword>
</DOC>